• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

缺氧诱导因子脯氨酰羟化酶抑制剂罗沙司他(FG-4592)可缓解脓毒症引起的急性肺损伤。

Hypoxia-inducible factor prolyl-hydroxylase inhibitor roxadustat (FG-4592) alleviates sepsis-induced acute lung injury.

机构信息

Department of Burns and Cutaneous Surgery, Xijing Hospital, Air Force Medical University, China.

Department of Burns and Cutaneous Surgery, Xijing Hospital, Air Force Medical University, China.

出版信息

Respir Physiol Neurobiol. 2020 Oct;281:103506. doi: 10.1016/j.resp.2020.103506. Epub 2020 Jul 26.

DOI:10.1016/j.resp.2020.103506
PMID:32726645
Abstract

Acute lung injury (ALI) is one of the most severe outcomes of sepsis which still waiting for effective treatment method. Roxadustat (FG-4592) which is often used for treatment of anemia in patients with chronic kidney disease (CKD), its affection on LPS-induced ALI haven't been evaluated. MH-S and MLE-12 cell injury and ALI mouse model was induced LPS. Several assays were used to explore the role of FG-4592 in reducing the damage caused by LPS. FG-4592 treatment significantly upregulated HIF-1α and HO-1 and strikingly attenuated inflammation in vivo and in vitro. Furthermore, septic mice overexpressing HIF-1α had high level of survival rate and lower expression of inflammatory factors while down-regulation can enhance the damage of LPS. HIF-1α has a protective effect on acute lung injury in LPS induced septic mice. FG-4592 treatment remarkably ameliorated the LPS-induced lung injury through the stabilization of HIF-1α. Besides the role in treating CKD anemia, the clinical use of FG-4592 also might be extended to ALI.

摘要

急性肺损伤(ALI)是脓毒症最严重的后果之一,目前仍缺乏有效的治疗方法。罗沙司他(FG-4592)常用于治疗慢性肾脏病(CKD)患者的贫血,但其对脂多糖(LPS)诱导的 ALI 的影响尚未得到评估。本研究采用 LPS 诱导 MH-S 和 MLE-12 细胞损伤及 ALI 小鼠模型,探讨 FG-4592 减轻 LPS 损伤的作用。结果显示,FG-4592 治疗可显著上调 HIF-1α 和 HO-1,显著减轻体内外炎症。此外,过表达 HIF-1α 的脓毒症小鼠存活率较高,炎症因子表达较低,而下调 HIF-1α 可加重 LPS 的损伤。HIF-1α 对 LPS 诱导的脓毒症小鼠急性肺损伤具有保护作用。FG-4592 通过稳定 HIF-1α 显著改善 LPS 诱导的肺损伤。除了在治疗 CKD 贫血方面的作用外,FG-4592 的临床应用也可能扩展到 ALI。

相似文献

1
Hypoxia-inducible factor prolyl-hydroxylase inhibitor roxadustat (FG-4592) alleviates sepsis-induced acute lung injury.缺氧诱导因子脯氨酰羟化酶抑制剂罗沙司他(FG-4592)可缓解脓毒症引起的急性肺损伤。
Respir Physiol Neurobiol. 2020 Oct;281:103506. doi: 10.1016/j.resp.2020.103506. Epub 2020 Jul 26.
2
Hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) protects against cisplatin-induced acute kidney injury.缺氧诱导因子脯氨酰羟化酶抑制剂罗沙司他(FG-4592)可预防顺铂诱导的急性肾损伤。
Clin Sci (Lond). 2018 Apr 16;132(7):825-838. doi: 10.1042/CS20171625.
3
Hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) protects against renal ischemia/reperfusion injury by inhibiting inflammation.缺氧诱导因子脯氨酰羟化酶抑制剂罗沙司他(FG-4592)通过抑制炎症反应来保护肾脏免受缺血/再灌注损伤。
Ren Fail. 2021 Dec;43(1):803-810. doi: 10.1080/0886022X.2021.1915801.
4
Nonclinical Characterization of the Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat, a Novel Treatment of Anemia of Chronic Kidney Disease.缺氧诱导因子脯氨酰羟化酶抑制剂罗沙司他的非临床特征:慢性肾脏病贫血的一种新治疗方法。
J Pharmacol Exp Ther. 2020 Aug;374(2):342-353. doi: 10.1124/jpet.120.265181. Epub 2020 Jun 2.
5
Roxadustat Markedly Reduces Myocardial Ischemia Reperfusion Injury in Mice.罗沙司他显著减轻小鼠心肌缺血再灌注损伤。
Circ J. 2020 May 25;84(6):1028-1033. doi: 10.1253/circj.CJ-19-1039. Epub 2020 Mar 24.
6
FG-4592 Accelerates Cutaneous Wound Healing by Epidermal Stem Cell Activation via HIF-1α Stabilization.FG-4592通过稳定缺氧诱导因子-1α激活表皮干细胞来加速皮肤伤口愈合。
Cell Physiol Biochem. 2018;46(6):2460-2470. doi: 10.1159/000489652. Epub 2018 May 5.
7
Esketamine alleviates ferroptosis-mediated acute lung injury by modulating the HIF-1α/HO-1 pathway.依沙佐米通过调节 HIF-1α/HO-1 通路缓解铁死亡介导的急性肺损伤。
Int Immunopharmacol. 2024 Dec 5;142(Pt A):113065. doi: 10.1016/j.intimp.2024.113065. Epub 2024 Sep 6.
8
Roxadustat attenuates experimental pulmonary fibrosis in vitro and in vivo.罗沙司他在体外和体内减轻实验性肺纤维化。
Toxicol Lett. 2020 Oct 1;331:112-121. doi: 10.1016/j.toxlet.2020.06.009. Epub 2020 Jun 10.
9
Evaluation of the Carcinogenic Potential of Roxadustat (FG-4592), a Small Molecule Inhibitor of Hypoxia-Inducible Factor Prolyl Hydroxylase in CD-1 Mice and Sprague Dawley Rats.罗沙司他(FG-4592)对CD-1小鼠和斯普拉格-道利大鼠致癌潜力的评估,罗沙司他是一种缺氧诱导因子脯氨酰羟化酶的小分子抑制剂
Int J Toxicol. 2017 Nov/Dec;36(6):427-439. doi: 10.1177/1091581817737232. Epub 2017 Nov 19.
10
Activation of the hypoxia-inducible factor pathway by roxadustat improves glucose metabolism in human primary myotubes from men.罗沙司他激活低氧诱导因子通路可改善男性原代肌管的葡萄糖代谢。
Diabetologia. 2024 Sep;67(9):1943-1954. doi: 10.1007/s00125-024-06185-6. Epub 2024 May 30.

引用本文的文献

1
Dual Roles of Hypoxia-Inducible Factor 1 in Acute Lung Injury: Tissue-Specific Mechanisms and Therapeutic Modulation.缺氧诱导因子1在急性肺损伤中的双重作用:组织特异性机制与治疗调控
Cells. 2025 Jul 16;14(14):1089. doi: 10.3390/cells14141089.
2
Expression and Regulation of Hypoxia-Inducible Factor Signalling in Acute Lung Inflammation.急性肺炎症中缺氧诱导因子信号传导的表达与调控
Cells. 2024 Dec 30;14(1):29. doi: 10.3390/cells14010029.
3
Limning of HIF-2 and HIF-3 in the Tumor Microenvironment: Developing Concepts for the Treatment of Hypoxic Cancer.
肿瘤微环境中HIF-2和HIF-3概述:缺氧癌症治疗的发展概念
Curr Mol Med. 2024 May 17. doi: 10.2174/0115665240303179240427071748.
4
Unraveling the role of HIF-1α in sepsis: from pathophysiology to potential therapeutics-a narrative review.解析 HIF-1α 在脓毒症中的作用:从病理生理学到潜在治疗策略——叙述性综述。
Crit Care. 2024 Mar 27;28(1):100. doi: 10.1186/s13054-024-04885-4.
5
Discovery of the Active Compounds of the Ethyl Acetate Extract Site of (Thunb.) Blume for the Treatment of Acute Lung Injury.发现治疗急性肺损伤的(Thunb.)Blume 乙酸乙酯提取物部位的活性化合物。
Molecules. 2024 Feb 7;29(4):770. doi: 10.3390/molecules29040770.
6
MK8617 inhibits M1 macrophage polarization and inflammation the HIF-1α/GYS1/UDPG/P2Y pathway.MK8617 通过抑制 HIF-1α/GYS1/UDPG/P2Y 通路抑制 M1 巨噬细胞极化和炎症反应。
PeerJ. 2023 Jun 30;11:e15591. doi: 10.7717/peerj.15591. eCollection 2023.
7
Roxadustat: Do we know all the answers?罗沙司他:我们是否已经了解所有的答案?
Biomol Biomed. 2023 May 1;23(3):354-363. doi: 10.17305/bb.2022.8437.
8
Combined transcriptome and proteome analysis of yak PASMCs under hypoxic and normoxic conditions.牦牛 PASMCs 在低氧和常氧条件下的联合转录组和蛋白质组分析。
PeerJ. 2022 Nov 25;10:e14369. doi: 10.7717/peerj.14369. eCollection 2022.
9
Risk of infection in roxadustat treatment for anemia in patients with chronic kidney disease: A systematic review with meta-analysis and trial sequential analysis.罗沙司他治疗慢性肾脏病患者贫血的感染风险:一项系统评价、荟萃分析及试验序贯分析
Front Pharmacol. 2022 Sep 16;13:967532. doi: 10.3389/fphar.2022.967532. eCollection 2022.
10
Roxadustat: Not just for anemia.罗沙司他:不止用于贫血。
Front Pharmacol. 2022 Aug 29;13:971795. doi: 10.3389/fphar.2022.971795. eCollection 2022.